Blood Conservation in Cardiopulmonary Transplantation

  • Nabeel G. El-Amir
  • Justin S. Kang
  • Craig R. Smith
Chapter

Abstract

In 1964 performance of a valve replacement without transfusion was a reportable event.1 The rapid growth of cardiac surgery in the late 1970s placed increasing demands on the blood supply, leading to a proportional increase over the next decade in literature describing techniques for blood conservation in routine cardiac surgery.2–5 It was logical that these techniques would be applied to cardiac transplant as that procedure entered a period of exponential growth in the 1980s, and it was not long before case reports marked the performance of cardiac transplants without blood or blood products in Jehovah’s Witnesses.6,7

Keywords

Hepatitis Pancreatitis Cyclosporine Thrombocytopenia Cardiol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cooley DA, Bloodwell RD, Beall AC. Cardiac valve replacement without blood transfusion.Am J Surg 1964;112:743–751.CrossRefGoogle Scholar
  2. 2.
    Toy PTCY, Strauss RG, Stehling LC, et al. Predeposited autologous blood for elective surgery.N Engl J Med 1987;316:517–520.PubMedCrossRefGoogle Scholar
  3. 3.
    Love TR, Hendren WG, O’Keefe DD, et al. Transfusion of predonated autologous blood in elective cardiac surgery.Ann Thorac Surg 1987;43:508–512.PubMedCrossRefGoogle Scholar
  4. 4.
    Moran JM, Babka R, Silberman S, et al. Immediate centrifugation of oxygenator contents after cardiopulmonary bypass.J Thorac Cardiovasc Surg 1978;76:510–517.PubMedGoogle Scholar
  5. 5.
    Cosgrove DM, Loop FD, Lytle BW. Blood conservation in cardiac surgery.Cardiovasc Clin 1982;12:165–175.Google Scholar
  6. 6.
    Corno AF, Laks H, Warner Stevenson L, et al. Heart transplantation in a Jehovah’s Witness.J Heart Transplant 1986;5:175–177.PubMedGoogle Scholar
  7. 7.
    Lammermeier DE, Duncan JM, Kuykendall RC, et al. Cardiac transplantation in a Jehovah’s Witness.Tex Heart Institute J 1988;15:189–192.Google Scholar
  8. 8.
    Kemkes BM. Hemostatic failures and heart-lung transplantation: assessing the current situation.J Heart Lung Transplant 1993;12:3–6.Google Scholar
  9. 9.
    Miller LW, Naftel DC, Bourge RC, et al. Infection after heart transplantation: a multiinstitutional study.J Heart Lung Transplant 1994;13:381–393.PubMedGoogle Scholar
  10. 10.
    Kaye MP. The registry of the International Society for Heart and Lung Transplantation: tenth official report—1993.J Heart Lung Transplant 1993;12:541–548.PubMedGoogle Scholar
  11. 11.
    Deeg HJ. Graft-versus-host disease: host and donor views.Semin Hematol 1993;30:110–118.PubMedGoogle Scholar
  12. 12.
    Herman JG, Beschorner WE, Baughman KL, et al. Pseudo-graft-versus-host disease in heart and heart-lung recipients.Transplantation 1988;46:93–98.PubMedCrossRefGoogle Scholar
  13. 13.
    Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease.N Engl J Med 1990;323:315–321.PubMedCrossRefGoogle Scholar
  14. Burdine J, Perry EH, Kshettry VR, et al. Donor derived antibodies and hemolysis after ABO compatible but non-identical heart-lung and lung transplantation. Presented at the International Society for Heart and Lung Transplantation, April 5–8, 1995, San Francisco, CA.Google Scholar
  15. 15.
    Preiksaitis JK. Indications for the use of cytomegalovirus-seronegative blood products.Transf Med Rev 1991;5:1–17.CrossRefGoogle Scholar
  16. 16.
    Preiksaitis JK, Rosno S, Grumet C, et al. Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy.J Infect Dis 1983;147:974–981.PubMedCrossRefGoogle Scholar
  17. 17.
    Pollard RB. Cytomegalovirus infections in renal, heart, heart-lung and liver transplantation.Pediatr Infect Dis J 1988;7:97–102.CrossRefGoogle Scholar
  18. 18.
    Linder J. Infection as a complication of heart transplantation.J Heart Transplant 1988;7:390–394.PubMedGoogle Scholar
  19. 19.
    Prince AM, Szmuness W, Millian SJ, David DS. A serologic study of cytomegalovirus infections associated with blood transfusions.N Engl J Med 1971;284:1125–1131.PubMedCrossRefGoogle Scholar
  20. 20.
    Duncan AJ, Dummer JS, Paradis IL, et al. Cytomegalovirus infection and survival in lung transplant recipients.J Heart Lung Transplant 1991;10:638–646.PubMedGoogle Scholar
  21. 21.
    Maurer JR, Tullis E, Scavuzzo M, et al. Cytomegalovirus infection in isolated lung transplantations.J Heart Lung Transplant 1991;10:647–649.PubMedGoogle Scholar
  22. 22.
    Onorato IM, Morens DM, Martone WJ, et al. Epidemiology of cytomegaloviral infections: recommendations for prevention and control.Rev Infect Dis 1985;7:479–497.PubMedCrossRefGoogle Scholar
  23. 23.
    Koskinen PK, Krogerus LA, Nieminen MS, et al. Cytomegalovirus infection- associated generalized immune activation in heart allograft recipients: a study of cellular events in peripheral blood and endomyocardial biopsy specimens.Transpl Int 1994;7:163–171.PubMedCrossRefGoogle Scholar
  24. 24.
    Normann SJ, Salomon DR, Leelachaikul P, et al. Acute vascular rejection of the coronary arteries in human heart transplantation: pathology and correlations with immunosuppression and cytomegalovirus infection.J Heart Lung Transplant 1991;10:674–687.PubMedGoogle Scholar
  25. 25.
    Novick RJ, Menkis AH, McKenzie FN, et al. Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status?J Heart Transplant 1990;9:699–706.PubMedGoogle Scholar
  26. 26.
    Hosenpud JD, Novick RJ, Breen TJ, et al. The Registry of the International Society for Heart and Lung Transplantation: eleventh official report—1994.J Heart Lung Transplant 1994;13:562–570.Google Scholar
  27. 27.
    Sayers M. Prevention of cytomegalovirus infection by using leukocyte-depleted components.Curr Stud Hematol Blood Transf 1994;60:41–52.Google Scholar
  28. 28.
    Lane TA. Leukocyte reduction of cellular blood components: effectiveness, benefits, quality control, and costs.Arch Pathol Lab Med 1994;118:392–404.PubMedGoogle Scholar
  29. 29.
    De Graan-Hentzen YCE, Gratama JW, Mudde GC, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products.Transfusion 1989;29:757–760.PubMedCrossRefGoogle Scholar
  30. 30.
    Matthews JL, Sogandares-Bernal F, Judy M, et al. Inactivation of viruses with photoactive compounds.Blood Cells 1992;18:75–89.PubMedGoogle Scholar
  31. 31.
    McCarty M. Of cats and women.Br Med J 1983;287:445–446.CrossRefGoogle Scholar
  32. 32.
    Fleck DG. Toxoplasmosis.Public Health 1969;83:131–135PubMedCrossRefGoogle Scholar
  33. 33.
    Holliman RE, Johnson JD, Adams S, et al. Toxoplasmosis and heart transplantation.J Heart Transplant 1991;10:608–610.Google Scholar
  34. 34.
    Ryning FW, McLeod R, Maddox JC, et al. Probable transmission ofToxoplasma gondiiby organ transplantation.Ann Intern Med 1979;90:47–49.PubMedGoogle Scholar
  35. 35.
    Wreghitt TG, Hakim M, Gray JJ, et al. Toxoplasmosis in heart and heart and lung transplant recipients.J Clin Pathol 1989;42:194–199.PubMedCrossRefGoogle Scholar
  36. 36.
    Luft BJ, Naot Y, Araujo FG, et al. Primary and reactivatedToxoplasmainfection in patients with cardiac transplants: clinical spectrum and problems in diagnosis in a defined population.Ann Intern Med 1983;99:27–31.PubMedGoogle Scholar
  37. 37.
    Anthuber M, Kemkes BM, Heiss MM, et al. HIV infection after heart transplantation: a case report.J Heart Transplant 1991;10:611–613.Google Scholar
  38. 38.
    Scorza LB, Waymack JP, Pruitt BA. The effect of transfusions on the incidence of bacterial infection.Milit Med 1990;155:337–339.Google Scholar
  39. 39.
    Waymack JP, Robb E, Alexander JW. Effect of transfusion on immune function in a traumatized animal model. II. Effect on mortality rate following septic challenge.Arch Surg 1987;122:935–939.PubMedGoogle Scholar
  40. 40.
    Waymack JP, Warden GD, Alexander JW, et al. Effect of blood transfusion and anesthesia on resistance to bacterial peritonitis.J Surg Res 1987;42:528–535.PubMedCrossRefGoogle Scholar
  41. 41.
    Tartter PI, Quintero S, Barron DM. Perioperative blood transfusion associated with infectious complications after colorectal cancer operations.Am J Surg 1986;152:479–482.PubMedCrossRefGoogle Scholar
  42. 42.
    Larison PJ, Cook LO. Adverse effects of blood-transfusion. In: Harmening DM, ed.Modern Blood Banking and Transfusion Medicine. 3rd ed. Philadelphia: F.A. Davis, 1994;351–374.Google Scholar
  43. 43.
    Stoelting RK, Miller RD. Fluid and blood therapy. In: Stoelting RK, Miller RD, eds.Basics of Anethesia. 3rd ed. New York: Churchill Livingstone, 1994;233.Google Scholar
  44. 44.
    Pennington DG, McBride LR, Swartz MT, et al. Use of Pierce-Donachy ventricular assist device in patients with cardiogenic shock after cardiac operations.Ann Thorac Surg 1989;47:130–135.PubMedCrossRefGoogle Scholar
  45. 45.
    Schiessler A, Friedel N, Weng Y, et al. Mechanical circulatory support and heart transplantation: pre-operative status and outcome.ASAIO J 1994;40:476–481.CrossRefGoogle Scholar
  46. 46.
    Aster RH, George JN. Thrombocytopenia due to sequestration of platelets. In: Williams WJ, Beutler E, Erslev AJ, Lictman MA, eds.Hematology. 4th ed. New York: McGraw-Hill, 1990;1398–1400.Google Scholar
  47. 47.
    Aster RH, George JN. Thrombocytopenia due to platelet loss. In: Williams WJ, Beutler E, Erslev AJ, Lictman MA, eds.Hematology. 4th ed. New York: McGraw-Hill, 1990;1401–1402.Google Scholar
  48. 48.
    Hunt BJ, Sack D, Amin S, et al. The perioperative use of blood components during heart and heart-lung transplantation.Transfusion 1992;32:57–62.PubMedCrossRefGoogle Scholar
  49. 49.
    Royston D. Aprotinin therapy in heart and heart-lung transplantation.J Heart Lung Transplant 1993;12:19–25.Google Scholar
  50. 50.
    Goodnough LT, Rudnick S, Price TH, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy.N Engl J Med 1989;321:1163–1168.PubMedCrossRefGoogle Scholar
  51. 51.
    Blackburn MEC, Kendall RG, Gibbs JL, et al. Anaemia in children following cardiac transplantation: treatment with low dose human recombinant erythropoietin.Int J Cardiol 1992;36:263–266.PubMedCrossRefGoogle Scholar
  52. 52.
    Schonberger JPAM, Bredée JJ, Tjian D, et al. Intraoperative predonation contributes to blood saving. Ann Thorac Surg 1993;56:893–898.PubMedCrossRefGoogle Scholar
  53. 53.
    Okita Y, Miki S, Ueda Y, et al. Reduction of homologous blood transfusion in reoperative valve surgery.J Heart Valve Dis 1994;3:411–416.PubMedGoogle Scholar
  54. 54.
    Wagstaffe JG, Clarke AD, Jackson PW. Reduction of blood loss by restoration of platelet levels using fresh autologous blood after cardiopulmonary bypass.Thorax 1972;27:410–414.PubMedCrossRefGoogle Scholar
  55. 55.
    Kaplan JA, Cannarella C, Jones EL, et al. Autologous blood transfusion during cardiac surgery: a re-evaluation of three methods.J Thorac Cardiovasc Surg 1977;74:4–10.PubMedGoogle Scholar
  56. 56.
    Novick RJ, Menkis AH, McKenzie FN, et al. Reduction in bleeding after heart-lung transplantation: the importance of posterior mediastinal hemostasis.Chest 1990;98:1383–1387.PubMedCrossRefGoogle Scholar
  57. 57.
    Vouhé PR, Dartevelle PG. Heart-lung transplantation: technical modifications that may improve the early outcome.J Thorac Cardiovasc Surg 1989;97:906–910.PubMedGoogle Scholar
  58. 58.
    Hackmann T, Gascoyne RD, Naiman SC, et al. A trial of desmopressin (l-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery.N Engl J Med1989; 321: 1437 – 1443.PubMedCrossRefGoogle Scholar
  59. 59.
    Addonizio VP, Fisher CA, Jenkin BK, et al. Iloprost (ZK36374), a stable analog of prostacyclin, preserves platelets during simulated extracorporeal circulation.J Thorac Cardiovasc Surg 1985;89:926–933.PubMedGoogle Scholar
  60. 60.
    Dietrich W, Barankay A, Dilthey G, et al. Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application: clinical experience in 152 cardiac surgical patients.Thorac Cardiovasc Surg 1989;37:92–98.PubMedCrossRefGoogle Scholar
  61. 61.
    von Segesser LK, Weiss BM, Garcia E, et al. Reduction and elimination of systemic heparinization during cardiopulmonary bypass.J Thorac Cardiovasc Surg 1992;103:790–799.Google Scholar
  62. 62.
    Cardoso PFG, Yamazaki F, Keshavjee S, et al. A reevaluation of heparin requirements for cardiopulmonary bypass.J Thorac Cardiovasc Surg 1991;101:153–160.PubMedGoogle Scholar
  63. 63.
    Royston D, Bidstrup BP, Taylor KM, et al. Effect of aprotinin on need for blood transfusion after repeat open heart surgery. Lancet 1987;2:1289–1291.PubMedCrossRefGoogle Scholar
  64. 64.
    Fraedrich G, Weber C, Bernard C, et al. Reduction of blood transfusion requirement in open heart surgery by administration of high dose of aprotinin: preliminary results.Thorac Cardiovasc Surg 1989;37:89–91.PubMedCrossRefGoogle Scholar
  65. 65.
    Dietrich W, Barankay A, Dilthey G, et al. Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application. Clinical experience in 152 cardiac surgical patients.Thorac Cardiovasc Surg 1989;37:92–98.PubMedCrossRefGoogle Scholar
  66. 66.
    Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.J Thorac Cardiovasc Surg 1993;106:1–10.PubMedGoogle Scholar
  67. 67.
    Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study.Ann Thorac Surg 1992;54:1031–1038.PubMedCrossRefGoogle Scholar
  68. 68.
    Bidstrup BP, Underwood SR, Sapsford RN, et al. Effect of aprotinin (trasylol) on aorta-coronary bypass graft patency.J Thorac Cardiovasc Surg 1993;105:147–153.PubMedGoogle Scholar
  69. 69.
    Blauhut B, Gross C, Necek S, et al. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass.J Thorac Cardiovasc Surg 1991;101:958–967.PubMedGoogle Scholar
  70. 70.
    Sundt TM, Kouchoukos NT, Saffitz JE, et al. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest.Ann Thorac Surg 1993;55:1418–1424.PubMedCrossRefGoogle Scholar
  71. 71.
    Royston D. High-dose aprotinin therapy: a review of the first five years experience.J Cardiothorac Vase Anesth 1992;6:76–100.CrossRefGoogle Scholar
  72. 72.
    Pae WE, Aufiero TX, Weldner PW, et al. Aprotinin therapy for insertion of ventricular assist devices for staged heart transplantation.J Heart Lung Transplant 1994;13:811–816.PubMedGoogle Scholar
  73. 73.
    Goldstein DJ, Seldomridge JA, Chen JM, et al. Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality.Ann Thorac Surg 1995;59:1063–1068.PubMedCrossRefGoogle Scholar
  74. 74.
    Levy JH. Antibody formation after drug administration during cardiac surgery: parameters for aprotinin use.J Heart Lung Transplant 1993;12:26–32.Google Scholar
  75. 75.
    Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: a double-blind randomized trial.N Engl J Med 1986;314:1402–1406.PubMedCrossRefGoogle Scholar
  76. 76.
    Czer LS, Bateman TM, Gray RJ, et al. Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin.J Am Coll Cardiol 1987;9:1139–1147.PubMedCrossRefGoogle Scholar
  77. 77.
    Temeck BK, Bachenheimer LC, Katz NM, et al. Desmopressin acetate in cardiac surgery: a double-blind, randomized study.South Med J 1994;87:611–615.PubMedCrossRefGoogle Scholar
  78. 78.
    Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding.Ann Thorac Surg 1994;58:1580–1588.PubMedCrossRefGoogle Scholar
  79. 79.
    Schaff HV, Hauer JM, Bell WR, et al. Autotransfusion of shed mediastinal blood after cardiac surgery.J Thorac Cardiovasc Surg 1978;75:632–641.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1998

Authors and Affiliations

  • Nabeel G. El-Amir
  • Justin S. Kang
  • Craig R. Smith

There are no affiliations available

Personalised recommendations